Novel KRAS Gene Mutations in Sporadic Colorectal Cancer by Naser, Walid M et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Novel KRAS Gene Mutations in Sporadic Colorectal Cancer
Citation for published version:
Naser, WM, Shawarby, MA, Al-Tamimi, DM, Seth, A, Al-Quorain, A, Nemer, AMA & Albagha, OME 2014,
'Novel KRAS Gene Mutations in Sporadic Colorectal Cancer' PLoS One, vol. 9, no. 11, pp. e113350. DOI:
10.1371/journal.pone.0113350
Digital Object Identifier (DOI):
10.1371/journal.pone.0113350
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
PLoS One
Publisher Rights Statement:
Copyright: © 2014 Naser et al. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Novel KRAS Gene Mutations in Sporadic Colorectal
Cancer
Walid M. Naser1, Mohamed A. Shawarby2*, Dalal M. Al-Tamimi2, Arun Seth3, Abdulaziz Al-Quorain4,
Areej M. Al Nemer2, Omar M. E. Albagha5
1Molecular Diagnostics Lab, Department of Laboratory Medicine, King Fahd Hospital of the University, University of Dammam, Al-Khobar, Saudi Arabia, 2 Pathology
Department, College of Medicine, University of Dammam, Dammam, Saudi Arabia, 3Molecular Diagnostics, Department of Anatomic Pathology, Sunnybrook Health
Sciences Centre, Toronto, Ontario, Canada, 4Department of Internal Medicine, College of Medicine, University of Dammam, Dammam, Saudi Arabia, 5 Rheumatology
Section, Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh,
United Kingdom
Abstract
Introduction: In this article, we report 7 novel KRAS gene mutations discovered while retrospectively studying the
prevalence and pattern of KRAS mutations in cancerous tissue obtained from 56 Saudi sporadic colorectal cancer patients
from the Eastern Province.
Methods: Genomic DNA was extracted from formalin-fixed, paraffin-embedded cancerous and noncancerous colorectal
tissues. Successful and specific PCR products were then bi-directionally sequenced to detect exon 4 mutations while
Mutector II Detection Kits were used for identifying mutations in codons 12, 13 and 61. The functional impact of the novel
mutations was assessed using bioinformatics tools and molecular modeling.
Results: KRAS gene mutations were detected in the cancer tissue of 24 cases (42.85%). Of these, 11 had exon 4 mutations
(19.64%). They harbored 8 different mutations all of which except two altered the KRAS protein amino acid sequence and all
except one were novel as revealed by COSMIC database. The detected novel mutations were found to be somatic. One
mutation is predicted to be benign. The remaining mutations are predicted to cause substantial changes in the protein
structure. Of these, the Q150X nonsense mutation is the second truncating mutation to be reported in colorectal cancer in
the literature.
Conclusions: Our discovery of novel exon 4 KRAS mutations that are, so far, unique to Saudi colorectal cancer patients may
be attributed to environmental factors and/or racial/ethnic variations due to genetic differences. Alternatively, it may be
related to paucity of clinical studies on mutations other than those in codons 12, 13, 61 and 146. Further KRAS testing on a
large number of patients of various ethnicities, particularly beyond the most common hotspot alleles in exons 2 and 3 is
needed to assess the prevalence and explore the exact prognostic and predictive significance of the discovered novel
mutations as well as their possible role in colorectal carcinogenesis.
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Introduction
The development of cancer (carcinogenesis) is a multistep
process that is believed to result from accumulation of genetic
alterations in a single cell during the life of an individual. The
number of genes found to be associated with different cancers is
growing rapidly. The most frequently activated genes are members
of the RAS gene family, two of which (Harvey- H) and (Kirsten-K)
were first identified as being homologous to viral transforming
genes, while the third (NRAS) was identified in a human
neuroblastoma. The RAS gene product is a monomeric
membrane-localized G protein of 21 kd that functions as a
molecular switch linking receptor and non-receptor tyrosine kinase
activation to downstream cytoplasmic or nuclear events. Each
mammalian cell contains at least three distinct RAS proto-
oncogenes encoding closely related, but distinct proteins. RAS
genes can be activated by various point mutations including those
affecting codons 12, 13, 61, or 113–117. Signal transduction by ras
proteins involves hydrolysis of GTP, and activating mutations
inhibit this process, locking the protein in the ‘‘on’’ signaling
conformation [1]. Activating mutations in these RAS proteins
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result in constitutive signaling, thereby stimulating cell prolifera-
tion, and inhibiting apoptosis.
Oncogenic KRAS mutations are prevalent in virtually all
cancer types, making KRAS one of the most frequently mutated
genes in human cancers [2]. The RAS oncogenes, together with
the p53 tumor-suppressor gene, are the genes most consistently
found to be mutated in colorectal cancer [3–4] in which epithelial
cells of the colorectum progress from small adenoma through large
adenoma, and finally become adenocarcinoma [3].
Numerous studies have reported the frequency of KRAS gene
mutations in colorectal cancer. The largest series was the
‘‘RASCAL’’ study of 2721 colorectal cancer cases reporting an
incidence of 37.7% [5]. Comparable frequencies were reported
subsequently [6–8].
The aim of this article is to report seven novel KRAS mutations
and open the door for further KRAS testing on a large number of
patients in order to assess the prevalence and explore the exact
prognostic and predictive significance of the discovered mutations
as well as their possible role in colorectal carcinogenesis. The novel
mutations were discovered while retrospectively studying the
prevalence and pattern of KRAS mutations in cancerous tissue
obtained from 56 Saudi sporadic colorectal cancer patients from
the Eastern Province, and correlating these with clinical features,
and p53, EGFR (epidermal growth factor) and HER2 (human
epidermal growth factor receptor2) protein expression, and EGFR
gene mutational status. It was not our intention to explore all
possible KRAS mutations that may be found in colorectal cancer,
so we just targeted the mutations that are commonly involved in
that disease. The discovery of new mutations came just by chance
while performing the study. To the best of our knowledge, this is
the first study on the pattern of KRAS gene mutations in Saudi
colorectal cancer patients.
Materials and Methods
Ethics statement
The study was approved by the Standing Committee of
Research Ethics on Living Creatures (SCRELC) which is the
IRB of our institution (Approval Number: IRB-2014-01-324). It
was not possible to obtain written informed consent from
participants as most of the patients were lost to follow up. This
issue was discussed with the committee which concurred that, in
keeping with the ‘‘Guidelines for Ethical Research Practice’’ [9],
consent is not required in such a retrospective study as the
information utilized by the authors was already accessible to the
public and did not disclose patient identity. Moreover, the study
carried no risk to the participants.
Fifty-six sporadic colorectal carcinoma cases of Saudi patients
were retrieved from the archives of the Pathology Department of
King Fahd Hospital of the University. The cases were randomly
Table 1. Primers used for KRAS exon 4 mutation analysis.
Primer Name Primer Sequence Amplicon Size Purpose
KRAS4-F 59-AGACACAAAACAGGCTCAGGA-39 160 bp 1st round PCR
KRAS4-R 59-TTGAGAGAAAAACTGATATATTAAATGAC-39
NKRAS4-M13F 59-tgtaaaacgacggccagtGACACAAAACAGGCTCAGGACT-39 105 bp Nested-PCR
NKRAS4-M13R 59-caggaaacagctatgaccCAGATCTGTATTTATTTCAGTGTTA-39
M13-F 59- tgtaaaacgacggccagt -39 Sequencing
M13-R 59- caggaaacagctatgacc -3
doi:10.1371/journal.pone.0113350.t001
Table 2. Mutations detected in exon 4. Exon 4 of all samples was sequenced as described in text.
Sample Code Codon Change p.Mutant (1) p.Mutant (3) c.Mutant
Concomittant Exon 2
(Codon 12) Mutation Comment
3 GCA.ACA p.A146T p.Ala146Thr c.436G.A none previously reported
32 GCA.GTA p.A134V p.Ala134Val c.401C.T GGT.GAT (p.G12D, c.35G.A) novel
33 AGA.AAA p.R135K p.Arg135Lys c.404G.A none novel
41 CAG.TAG p.Q150X p.Gln150Stop c.448C.T none novel
44 AAG.AAA p.K147K p.Lys147Lys c.441G.A none novel
45 CAG.TAG p.Q150X p.Gln150Stop c.448C.T GGT.GAT (p.G12D, c.35G.A) novel
48 GAA.AAA p.E143K p.Glu143Lys c.427G.A none novel
50 GGA.GGG p.G138G p.Gly138Gly c.414A.G none novel
51 AGA.GGA p.R149G p.Arg149Gly c.444A.G none novel
53 GGA.GGG p.G138G p.Gly138Gly c.414A.G none novel
61 GGA.GGG p.G138G p.Gly138Gly c.414A.G none novel
Fifty six colorectal cancer tissue samples were analyzed. Only those with a mutation in exon 4 are illustrated in the table. All detected mutations were confirmed via
sequencing the opposite strand. HGVS guidelines for mutation nomenclature were followed.
doi:10.1371/journal.pone.0113350.t002
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selected based on the availability of clinical data and representative
paraffin tissue blocks sufficient to perform the required procedures,
as well as negative family history for colorectal cancer. The time
frame covered was 11 years (1998–2008).
Clinical and pathological data
Clinical and pathological data including histologic type, grade
and stage of the cancer were collected from the patients’ records.
Figure 1. Images of Sanger sequencing electropherogram showing novel mutations (left panel) detected in the study cohort
(reverse direction) and the corresponding wild type sequence (right panel) of normal tissue sections for the same patient
indicating the somatic origin of detected exon 4 mutations. All illustrated mutations were confirmed via sequencing the forward strand.
Sample number and mutation nomenclature according to HGVS guidelines are highlighted above each mutation. Arrows point to the location of
base pair change.
doi:10.1371/journal.pone.0113350.g001
Novel KRAS Mutations
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Clinical and pathological data were classified using WHO criteria
[10].
Immunohistochemical staining
Immunohistochemical staining was performed for EGFR,
HER2 and p53 on 4 mm-thick paraffin sections cut from blocks
of colorectal carcinomatous tissue. The staining was performed in
a Ventana Benchmark automated immunostainer according to the
manufacturer’s instructions (Ventana Medical Systems Inc.,
Strasbourg). Sources and dilutions of the primary antibodies used
in the study are shown in Table S1. The immunostained sections
were examined under a light microscope and evaluated manually
by two pathologists. Definite membrane and/or cytoplasmic
staining was necessary to consider a case as EGFR or HER2/
neu positive, while nuclear staining of at least 10% of the cancer
cells was needed for p53 positivity (Figure S1).
Genomic DNA extraction
Five to eight 10 mm-thick formalin-fixed, paraffin-embedded
cancerous tissue sections were used to extract genomic DNA.
Sections were deparaffinized twice for 5 minutes in xylene,
sequentially rehydrated in 100, 96 and 70% ethanol for 30
seconds each, stained with haematoxylin for 30 seconds, rinsed
with water and incubated overnight in 1 M NaSCN at 37uC to
remove cross-links. Slides were rinsed twice for 10 minutes in 16
PBS at room temperature, and completely air-dried. As indicated
by an experienced pathologist, cancerous tissue was scraped from
the glass slide surface with a scalpel to obtain at least 70% tumor
cells and then transferred to 2.0 ml micro-centrifuge tubes.
Genomic DNA was then extracted using the WaxFree DNA Kit
(TrimGen, Maryland) implementing the standard protocol
described by the manufacturer with overnight incubation in step
14 of the protocol. Extracted genomic DNA was quantified with
Epok spectrophotometer and analyzed by 0.8% agarose gel
electrophoresis to visualize DNA size distribution.
For those patients who exhibited novel KRAS exon 4
mutations, we also extracted genomic DNA from noncancerous
colorectal tissue as described above. The noncancerous tissue was
obtained from a tumor free resection margin from the colectomy
specimen of the same patient.
PCR amplification of KRAS exon 4
Sequencing was applied to detect KRAS exon 4 mutations as
kits for detection of A146T - which is the exon 4 mutation
reported to be commonly involved in colorectal cancer [11–12] -
were not commercially available. A nested PCR approach similar
Figure 2. Shifted Termination Assay control for codon 12 mutations (top panel): 1st red peak: GGT.AGT; 1st blue peak: GGT.CGT;
2nd blue peak: GGT.GCT; 2nd red peak: GGT.GAT; 1st black peak: GGT.TGT; 2nd black peak: GGT.GTT; 3rd black peak: wild
type. Bottom panel is for sample 32 showing the 2nd red peak (GGT.GAT) and the 3rd black peak (wild type).
doi:10.1371/journal.pone.0113350.g002
Novel KRAS Mutations
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to that adopted by Fadhil, et al [13] was implemented to amplify
and perform melting analysis for exon 4 of the KRAS gene in
order to check for successful PCR reactions and specificity. The
first PCR round was undertaken in a final volume of 25 ml. Each
reaction contained 16 QIAGEN Multiplex PCR Master Mix,
0.56 Q-solution, 2 primer pairs (Table 1) covering hotspots in
KRAS exon 4 with 0.3 mM final concentration for each primer
and 10 ng template DNA. PCR was performed using ABI’s Veriti
Thermal Cycler (Life Technologies) for 15 minutes at 95uC, 40
cycles each of 30 seconds at 94uC, 90 seconds at 55uC and 90
seconds at 72uC, followed by 10 minutes at 72uC. After addition of
2 ml (5 x) loading dye, 10 ml of each amplified sample was
electrophoresed on a 2% TBE agarose ethidium bromide-stained
gel and visiualized with GelDoc system from Biorad.
High resolution melting curve analysis (HRM) was performed
using nested PCR reaction in a final volume of 15 ml, which
contained 16 HRM Master Mix (Qiagen) and 1 primer pair
specific for exon 4 (Table 1) with each primer at 0.7 mM final
concentration. The template consisted of 1.5 ml of a 1:100 dilution
of the product from the first round PCR reaction. Nested PCR
reaction was performed as described in the instruction manual of
the HRM Type-it Kit (Qiagen).
HRM is used to assess the dissociation (melting) characteristics
of double-stranded DNA (dsDNA). Base-pair composition and GC
content influence melting behavior of different dsDNA fragments.
During HRM, dsDNA is exposed to gradually increasing
temperature in the presence of a fluorescent dye (e.g. EvaGreen).
The fluorescent dye fluoresces only when bound to dsDNA.
Fluorescence is monitored during transition of dsDNA to single-
stranded DNA (ssDNA) which decreases as dsDNA melts. Plotting
changes in fluorescence after generating specific DNA fragments
during PCR give rise to single peaks corresponding to specific
amplicons [14].
DNA sequencing
After HRM, successful and specific PCR products showing one
melting peak were column purified using the QIAquick PCR
Purification Kit (Qiagen) according to the manufacturer’s instruc-
tions. The PCR products were eluted with 30 ml elution buffer and
diluted 1:10 with water. Diluted PCR products were then used as
template for cycle sequencing via Big Dye Terminator v1.1 kit
(Applied Biosystems). Bidirectional sequencing (i.e. forward and
reverse) was performed using cycle sequencing reaction (10 ml final
volume) consisting of 16 terminator premix, 16 sequencing
buffer, 0.4 mM of either M13-F or M13-R primers (Table 1) and
4 ml of diluted template. The reactions were run on Veriti (Life
Technologies) according to the following protocol: One cycle of
95uC for 15 minutes; 30 cycles of 95uC for 10 seconds, 55uC for 5
seconds, 72uC for 4 minutes. Sequencing reactions were purified
with ABI’s BigDye XTerminator Purification Kit (Life Technol-
ogies) and loaded on a 3500 Genetic Analyzer (Life Technologies).
Sequencing data were analyzed using Sequencing Analysis v5.4
and SeqScape v2.7 softwares (Life Technologies).
Shifted termination assays (STA)
STA is based on primer-extension methods where 3 oligonu-
cleotides (2 for amplification and 1 for mutation detection) are
used to detect a specific mutation. However, STA utilizes the
incorporation of multiple labeled nucleotides to the detection
primer as compared to incorporation of a single labeled nucleotide
in other primer-extension-based methods. The detection primer
anneals one base before the target site and is then extended only
when target site is mutated. Extension of detection primer with
multiple labeled nucleotides intensifies signal and increases PCR
fragment length allowing mutation discrimination from wild type
via peak color and fragment size after capillary electrophoresis
[15].
We used Mutector II Mutation Detection Kits (TrimGen,
Maryland) to identify mutations in codons 12, 13 and 61 of the
KRAS gene which are the KRAS mutations reported to be most
frequently involved in colorectal cancer [11–12], as well as specific
mutations of the EGFR gene in characteristic locations in exons
18–21, including certain point mutations, deletions and insertions
which identify patients who are most likely to respond to targeted
lung cancer therapy, including tyrosine kinase inhibitors erlotinib
and gefitinib. The Mutector II Mutation Detection Kits imple-
ment STA technology for the simultaneous detection and
differentiation of mutations occurring on the same target site.
Mutector II Mutation Detection Kit GP05-CM detects and
differentiates all 12 mutations occurring in codons 12 and 13 while
Mutector II Mutation Detection Kit GP06 is designed for 5
mutations occurring in codon 61. Mutector II Mutation Detection
Kit GP07-02 detects mutations in characteristic locations in exons
18–21 of the EGFR gene. STA technology significantly improves
sensitivity. It detects as low as 1% somatic mutations as compared
to 15–20% via Sanger sequencing [15]. Briefly, 50 ng gDNA was
PCR amplified using reagents provided via the PCR conditions
described by the manufacturer. PCR products were cleaned up
and mutations in codons 12, 13, and 61 were enriched separately
by mutation specific primer extension reaction. Samples contain-
ing enriched mutations were cleaned from excess fluorescent dyes,
diluted 5–10 times with water. Three microliters of the diluted
primer extension products were mixed with loading buffer
provided in the kit and fragment sized via capillary electrophoresis
on ABI’s 3500 Genetic Analyzer (Life Technologies). Capillary
electrophoresis running conditions and instrument setup for data
collection are explained in detail within the Mutector II Mutation
Kit instructions manual.
Table 3. Molecular modeling data of KRAS exon 4 non-synonymous mutations.
Mutation Polyphen-2 (score) SIFT (score) Mutation Assessor protein domain affected
A146T Probably Damaging (1.000) Deleterious (0.00) high TURN
A134V Possibly Damaging (0.635) Deleterious (0.00) medium HELIX
R135K Benign (0.000) Tolerated (0.73) neutral HELIX
E143K Possibly Damaging (0.788) Deleterious (0.01) high STRAND
R149G Probably Damaging (0.989) Deleterious (0.00) neutral TURN
Q150X N/A HELIX
doi:10.1371/journal.pone.0113350.t003
Novel KRAS Mutations
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Figure 3. Predicting molecular modeling of KRAS mutations identified in patients with colorectal cancer.Wild type (WT) KRAS is shown
in blue color and the mutant proteins are shown in yellow. The side chains of amino acids are shown in green for the WT residues and in red for the
mutant residues. a) WT K-RAS showing side chain of A134 (green). b) Overlap of WT and mutant A134V KRAS showing predicted conformational
changes caused by the A134V mutation (note the changes in the helix and beta sheet). c) Overlap of WT and mutant R135K KRAS showing predicted
conformational changes caused by the R135K mutation (note the changes in the helix and loop chains) but doesn’t affect the GTP binding pocket. d)
Overlap of WT and mutant E143K KRAS showing predicted conformational changes caused by the E143K mutation (note the changes in the loop near
the GTP binding pocket). e) Overlap of WT and mutant T144I KRAS showing predicted conformational changes caused by the T144I mutation (note
the changes in the GTP binding pocket and the changes in the orientation of the bound GTP; green is wt and red is mutant). f) Overlap of WT and
mutant R149G KRAS showing predicted conformational changes caused by the R149G mutation (note the changes in the helix and loop chains near
the GTP binding pocket). g) Overlap of WT and mutant Q150X KRAS showing predicted conformational changes caused by the Q150X mutation (note
the changes in the loop chain).
doi:10.1371/journal.pone.0113350.g003
Novel KRAS Mutations
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Functional prediction and molecular modeling of novel
KRAS mutations
The functional impact of the non-synonymous (protein structure
altering) exon 4 mutations was assessed using POLYPHEN-2
(polymorphism phenotyping v2) [16] and SIFT (sorting intolerant
from tolerant tools) [17]. We also used the mutation assessor [18]
to predict the functional impact of mutations based on evolution-
ary conservation of the affected amino acid in protein homologs.
Additionally, molecular modeling was applied to predict the
functional impact of the novel mutations detected. The K-ras
protein structure used for modeling was obtained from the Protein
Data Bank (PDB ID: 3gft). Modeling of mutations was performed
and visualised using PyMOL [19–20]. PyMOL displays informa-
tion on all steric interference between the mutated amino acid and
other amino acid side chains and the configuration with the least
steric interference is selected manually. The mutant side chains
were modeled into positions of the protein using rotamers with
lowest conflicting Van der Waals radii and the configuration with
the least steric interference with other amino acid side chains. The
wild type and the mutant protein structure were superimposed to
highlight the predicted conformational changes caused by each
mutation.
Statistical analysis
Data analysis was performed using SPSS for windows version
17.0 (SPSS Inc., Chicago, IL). Results were cross-tabulated to
examine the relationships between the variables. Statistical
analysis for categorical variables was performed using x-square
for test of association and Fisher’s exact test as appropriate. Where
two continuous independent variables were examined, t-test and
analysis of variance were used. A p-value of less than 0.05 is
considered significant in all statistical analyses.
Results
Novel KRAS mutations
KRAS gene mutations were detected in the cancer tissue of 24
out of 56 cases studied (42.85%). Of these, 11 (19.64%) had exon 4
mutations localized between codons 134 and 150, while 13
(23.21%) had mutations in exon 2, affecting codons 12 and 13.
Mutations were not detected in codon 61 of exon 3. The
distribution of mutations in our cohort is shown in Table S2.
The 11 cases with exon 4 aberrations harbored 8 different
mutations (Table 2) of which one was previously reported
(p.Ala146Thr, a missense mutation) and 7 were novel as revealed
by the COSMIC database accessed on 19/09/2014. We
confirmed all novel sequence variations detected in our cohort
by sequencing the opposite strand. All samples showed an identical
sequence variation in the opposite strand. The weak signal in
sample 33 (Figure 1) could be attributed to lower tumor tissue
content; the other (forward) strand also showed a weak signal of
the sequence variation (c.404G.A) as well. However, sequencing
the noncancerous tissue of the patient showed no signal
whatsoever for variation c.404G.A indicating that the signal in
the sample is above the detection limit of the sequencing protocol.
One of the novel mutations (G138G) was detected in three patients
and another (Q150X), detected in two other patients. Four of the
seven mutations were missense mutations altering the amino acid
sequence of the protein (A134V, R135K, E143K and R149G),
whereas two mutation were synonymous (G138G and K147K)
and one, a nonsense truncating mutation (Q150X). The missense
and nonsense exon 4 mutations were observed in seven patients
(12.5% of the total). Figure 1 is an electropherogram for the
KRAS exon 4 nonsense and missense mutations that truncated or
altered the KRAS protein amino acid sequence, respectively.
Samples 32 and 45 also contained another mutation (p.Gly12Asp)
in codon 12 of exon 2 as revealed by STA analysis, that was
frequently detected in colorectal cancer patients (Figure 2). The
novel exon 4 KRAS mutations were found to be somatic since
sections of noncancerous colorectal tissue from patients who
harbored those mutations showed the wild type sequence
(Figure 1).
The functional impact of the non-synonymous mutations on the
KRAS protein was assessed using bioinformatics tools and results
are presented in Table 3. For example, the E143K and Q150X
mutations are predicted to have a damaging and high impact on
the protein whereas the R135K is predicted to be tolerated or to
have neutral impact on the protein. Additionally we used
molecular modeling to assess the functional impact of these novel
KRAS mutations and results are shown in Figure 3. The
molecular modeling data fit with the prediction from POLY-
PHEN-2 and SIFT, as well as conservation data (Table 3). For
example, the R135K mutation is predicted to be benign and
modeling also showed little predicted effect on protein structure.
The remaining mutations are predicted to cause substantial
changes in the protein structure in line with the predicted
damaging effect by POLYPHEN-2.
Point mutations specified by the EGFR mutation detection kit
in exons 18, 20 and 21 of the EGFR gene were not detected in any
of the 56 cases studied. InDel mutations in exons 19 and 20 were
also not detected.
The main clinical, pathological and immunohistochem-
ical findings in the reported cases are shown in Table 4.
Tables 5 and 6 show a prevalence of female sex in cases with novel
KRAS mutations compared to cases with other KRAS mutations
and KRAS mutation negative cases (70%, 42.8% and 43.75%,
respectively). They also show lower prevalence of lymph node
metastasis and p53 expression although the differences are not
statistically significant (p value ranging between 0.078 and 1.0).
We did not find EGFR or HER2 protein expression, or EGFR
gene mutations in any of the 10 cases. There was also no
significant difference between the three groups regarding patient
age, and tumor size, depth and grade.
Three out of the five patients harboring the deleterious
mutations had more advanced disease with increased tumor depth
and lymph node metastasis (cases 32, 45 and 51), while two had
localized disease (cases 41 and 48).
The two cases with concomitant exon 2 mutation (cases 32 and
45) showed greater tumor size and depth compared to most of the
other cases with novel mutations and also had lymph node
metastasis.
Discussion
Activation of the KRAS oncogene has been implicated in
colorectal carcinogenesis, being mutated in 30–40% of adenocar-
cinomas [5–8], a prevalence comparable to that observed in the
present study (42.85%). The mRNA transcript of the KRAS gene
is composed of 5765 bases coding for 188 amino acids. Exons 1, 2,
3, 4, and 5 contain 181, 122, 179, 160, and 5123 bases,
respectively [21]. The majority of somatic mutations occur at
codons 12 and 13 (situated in exon 2). Other less frequent
mutations occur in exon 3 (codons 59/61) and exon 4 (codons
117/146) [22–23]. Approximately one third of colorectal cancers
harbored mutations at the G12 and G13 codons while exon 4
mutations codon 117 and 146 were detected in only up to 5.5% of
tumors [24]. Our study showed a much lower prevalence of exon 2
mutations (23.21%) and a much higher prevalence of exon 4
Novel KRAS Mutations
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mutations (19.64%) with the exon 4 mutations localized between
codons 134 and 150 rather than involving codons 117 and 146.
Exon 4 KRAS mutations are underestimated since all efforts of
clinical testing focused on exon 2 (codons 12 and 13) and exon 3
(codon 61) mutations [22–25]. All seven novel KRAS mutations
reported in the present article occurred in exon 4 and localized
between codons 134 and 150. Thus we suggest including codons
134–150 as a hotspot for routine KRAS mutational analysis in
colorectal cancer patients, rather than focusing only on codons
117 and 146. We detected missense and nonsense exon 4
mutations in 12.5% of the cases which is higher than what was
previously reported, which amounted to 10% but also included
exon 3 and NRAS in addition to exon 4 mutations [24]. All novel
mutations were found to be somatic since all sections of
noncancerous colorectal tissue from the 10 cases that harbored
the mutations showed the wild type sequence.
The functional impact of the novel non-synonymous mutations
on the KRAS protein was assessed using bioinformatics tools and
molecular modeling (Tables 2 & 3, Figure 3). The R135K
mutation resulted in the substitution of Arg for the similarly
charged Lys that is predicted to cause little changes in interactions
between adjacent residues. Bioinformatics tools showed that the
R135K mutation is predicted to have a neutral effect on the
protein. Similarly, molecular modeling showed a minor change to
the protein structure caused by this mutation (Figure 3). In
contrast, the E143K mutation is predicted to have a damaging
effect on the protein by bioinformatics tools (Table 3) and by
molecular modeling (Figure 3). This mutation resulted in the
substitution of the negatively charged Glu for the positively
charged Lys (Table 2) that is likely to cause major changes in the
interactions of the adjacent amino acid residues. Figure 3 shows
that the E143K mutation caused substantial changes to the
structure of the KRAS protein especially in the loop near the GTP
binding pocket. The R149G mutation is predicted to be neutral
but molecular modeling showed that this mutation caused changes
in the helix and loop chains near the GTP binding pocket. This is
likely to be due to the changes in the interactions between amino
acid residues caused by the substitution of the positively charged
Arg for the non-polar Gly (Table 2). Additionally, this mutation is
located near the conserved SAK motif and a recent study showed
that a nearby mutation (K147E) results in a self-activating RAS
protein that can act independently of upstream signals and exhibit
a lower affinity for RAF kinase [26]. The Q150X mutation
introduced a premature stop codon and is predicted to have an
effect on the stability of the mRNA through nonsense-mediated
decay resulting in reduced expression of the truncated protein. To
the best of our knowledge, the Q150X mutation detected in the
present study is the second KRAS truncating mutation to be
reported in colorectal cancer in the literature. A KRAS mutation
(CAG.TAG) determining a premature stop signal at codon 22
(Gln22Stop) has been previously found in a patient with metastatic
colorectal cancer by Palmirotta, et al [27]. BRAF and p53 genes
were not found to be modified and microsatellite instability was
not present. The patient, however, was found to be unresponsive
to an anti-EGFR treatment. Interestingly our two patients
harboring the truncating mutation were EGFR negative by
IHC. They also had no EGFR gene mutations. Several preclinical
[28] and clinical [29] studies have shown that the occurrence of
KRAS mutations in colorectal cancer is an independent predictive
parameter of EGFR targeted therapy resistance. Finally, although
the synonymous novel exon 4 mutations reported in the present
study (including the G138G mutation that was detected in three
patients) did not alter protein amino acid composition, they may
still prove significant in tumorogenesis. There is growing evidence
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Table 5. Clinical, pathological and immunohistochemical findings in colorectal cancer cases with novel K-ras mutations compared
to cases with other K-ras mutations.
All mutations N(%) Novel mutations N(%) p-value
Age (years) Mean(SD) 59.1(14.7) 59.4(16.7) 0.656
Tumor size/cm Mean(SD) 4.9(2.4) 5.5(1.59) 0.416
Tumor depth (pT) 1 1(7.1) 0(0) 0.733
2 3(21.4) 2(20)
3 9(64.3) 6(60)
4 1(7.1) 2(20)
Lymph node metastasis Absent 9(64.2) 7(70) 0.591
Present 5(35.7) 3(30)
Sex Male 8(57.1) 3(30) 0.129
Female 6(42.8) 7(70)
Tumor Grade Grade I 1(7.1) 2(20) 0.706
Grade II 12(85.7) 8(80)
Grade III 1(7.1) 0(0)
P53 Neg. 9(64.2) 8(80) 0.683
Pos. 5(35.7) 2(20)
EGFR Neg. 11(78.6) 10(100) 0.291
Pos. 3(21.4) 0(0)
HER2 Neg. 10(71.4) 10(100) 0.078
Pos. 4(28.6) 0(0)
Total Number 14 (100) 10(100)
doi:10.1371/journal.pone.0113350.t005
Table 6. Clinical, pathological and immunohistochemical findings in colorectal cancer cases with novel K-ras mutations compared
to K-ras mutation negative cases.
Mutation Negative N(%) Novel mutations N(%) p -value
Age (years) Mean(SD) 57.2(14.9) 59.4(16.7) 0.491
Tumor size/cm Mean(SD) 5.4(1.9) 5.5(1.9) 0.842
Tumor depth (pT) 1 0(0) 0(0)
2 5(15.62) 2(20)
3 22(68.75) 6(60)
4 5(15.62) 2(20) 0.877
Lymph node metastasis Absent 17(53.12) 7(70)
Present 15(46.87) 3(30) 0.473
Sex Male 18 (56.25) 3(30)
Female 14(43.75) 7(70) 0.277
Tumor Grade Grade I 2 (6.25) 2(20)
Grade II 26 (81.25) 8(80) 0.251
Grade III 4(12.5) 0(0)
P53 Neg. 23 (71.87) 8(80)
Pos. 9 (28.12) 2(20) 1.000
EGFR Neg. 23 (71.87) 10(100)
Pos. 9 (28.12) 0(0) 0.086
HER2 Neg. 25 (78.12) 10(100)
Pos. 7 (21.87) 0(0) 0.168
Total Number 32 (100) 10 (100)
doi:10.1371/journal.pone.0113350.t006
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that synonymous mutations (often erroneously referred to as
‘‘silent’’) can affect transcription, splicing, mRNA transport and
translation, any of which could alter phenotype, rendering the
synonymous mutation non-silent [30].
We detected one of the novel mutations in three cases (G138G)
and another in two more cases (Q150X). Our sample size is rather
small to conduct frequency analysis and comparison to larger
published studies. However, the fact that these new mutations
were seen in 5/56 cases indicates that further studies need to be
done.
EGFR is over expressed in many types of cancers, especially
colorectal cancer, and seems to reflect more aggressive histological
and clinical behaviors [31]. It has also been shown that p53
protein over expression may help in potentially predicting
metastatic spread to the lymph nodes in colorectal cancer [32].
Based on such information, the low prevalence of lymph node
metastasis and p53 expression in our patients harboring the novel
mutations coupled with the absence of EGFR and HER2 protein
expression and EGFR gene mutations may generally suggest a
low-grade pathway in colorectal cancer development in those
patients, who are probably also resistant to anti-EGFR and anti-
HER2 therapy. This speculation is in keeping with the finding that
mutations in exon 4 of KRAS predict for a more favorable clinical
outcome in patients with colorectal cancer [24]. Ironically, four of
the seven novel exon 4 mutations detected in the present study are
predicted to be deleterious to the KRAS protein as revealed by
molecular modeling. Moreover, only three out of the five patients
harboring the deleterious mutations had more advanced disease
with increased tumor depth and lymph node metastasis (cases 32,
45 and 51), while two had localized disease (cases 41 and 48)!
Could some of the mutations detected, alternatively, have a
beneficial rather than a harmful effect on the host, possibly
attributed to environmental factors? It has recently become clear
that mutant RAS may result in highly divergent consequences in
different tissues and environments [33]. For example, overexpres-
sion of HRasV12 in immortalized mouse NIH3T3 cells causes
transformation associated with activation of Raf and PI3K
pathways [34], whereas overexpression of HRas in normal
fibroblasts causes a senescent-like cell cycle arrest [35]. Over
expression of mutant RAS alleles results in a senescent-like
phenotype that has been attributed to increased production of
reactive oxygen species and associated stresses [36–37] and is likely
unrelated to the normal functions of single copy mutant RAS,
which results in tumor initiation without senescence [38]. It is to
be noted that the two cases with concomitant exon 2 mutation
(cases 32 and 45) showed greater tumor size and depth compared
to most of the other cases and also had lymph node metastasis.
The more extensive disease observed in those two cases may relate
to the synergetic effect of the concomitant exon 2 mutation rather
than a direct effect of the ‘‘deleterious’’ exon 4 mutations present.
It is known that multiple mutations appear to be associated with a
more aggressive disease [39].
The seemingly contradictory observations described above may,
however, be due to the small sample size studied. It remains,
therefore, that further more advanced KRAS testing, including
next generation sequencing (NGS), on a large number of patients,
particularly beyond the most common hotspot alleles in exons 2
and 3 is needed to explore the exact prognostic and predictive
significance of the discovered novel mutations as well as their
possible role in colorectal carcinogenesis.
Our discovery of novel Exon 4 KRAS mutations that are, so far,
unique to Saudi patients from the Eastern Province may be
attributed to environmental factors and/or genetic variation
amongst different racial/ethnic groups. Alternatively, it may again
be related to paucity of clinical studies on mutations other than
those at codons 12, 13, 61 and 146 [12] and could, in the future,
prove to be more frequent and non-race restricted.
The epidemiology of colorectal carcinoma in developing
countries differs from that of developed countries. Colorectal
carcinoma in developing countries, including those in the Middle
East, is usually characterized by low incidence, young age of onset,
left-sided location, poor differentiation, and paucity of precursor
adenomas [40–48]. It has been suggested that environmental
factors, especially lifestyle and dietary differences, play a major
role in the observed epidemiologic differences. A study involving a
number of Middle Eastern countries indicated that geographic
variation in methylation also exists in colorectal carcinoma,
possibly as a result of different environmental exposures [49].
Studies from various other countries have analyzed the frequency
of the type of K-ras gene point mutation in colorectal cancer.
Those studies were conducted in the UK [50–51], former
Yugoslavia [52], Czech Republic [53], Norway [54], Switzerland
[55], Mexico [56], USA [57] and The Netherlands [58–60]. All of
the studies except that performed in former Yugoslavia [52] have
identified the G.A transition as the most frequently found type of
K-ras mutation. The pattern of specific alterations observed, i.e.
G.A transitions and G.T transversions, could be due to
differences in diet and/or other lifestyle factors. N-nitroso
compounds, for example, in red and processed meat could induce
G.A transitions [51] and this is supported by previous
experimental studies [61–62]. A high intake of polyunsaturated
fat, in particular linoleic acid, may be an important dietary risk
factor for K-ras mutated colon tumors, possibly by generating G.
A transitions or G.T or G.C transversions in the K-ras
oncogene [11]. Interestingly, the meal that is mostly consumed in
Saudi Arabia consists of lamb and rice.
In addition or as an alternative to environmental factors, the
novel mutations detected may be attributed to genetic variation.
Population-based studies have shown differences in colorectal
cancer survival estimates that were reported to be higher in
developed countries in comparison to less developed nations, with
the exception of Eastern Europe [63–64]. Incidence rates in the
United States have also shown clear racial/ethnic disparities for
colorectal cancer. Incidence and mortality among Caucasians
were lower than among African-Americans, but higher than
among Asian and Pacific Islanders and Hispanics [65]. Five-year
survival was found similar in non-Hispanic whites and Asian
Americans [66–68]. It has been suggested that differences in the
distribution of known/suspected risk factors account for only a
modest proportion of the ethnic variation in colorectal cancer and
that other factors, possibly including genetic susceptibility, are
important contributors to the observed disparities [69]. It may be
interesting to note that studies on breast cancer patients from the
Eastern Province of Saudi Arabia revealed a spectrum of
molecular breast cancer types that was in stark contrast with
Western and other regionally based studies [70]. In a recent pilot
study performed on Canadian and Saudi breast cancer patient
populations, Amemiya, et al., using Next Generation SOLiD RNA
sequencing and Ion Torrent exome targeted sequencing technol-
ogies, found a high prevalence for an SNV in FAM175A gene
predicted to be deleterious in the Canadian as compared to the
Saudi patients. In addition, a high prevalence of MSH6 gene
deletions was seen in the Saudi patients, resulting in a frame shift
in the Saudi population compared to the Canadian population
[71].
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Conclusions
Our discovery of novel Exon 4 KRAS mutations that are, so far,
unique to Saudi colorectal cancer patients from the Eastern
Province may be attributed to environmental factors and/or
racial/ethnic variations due to genetic differences. Alternatively, it
may be related to paucity of clinical studies on mutations other
than those in codons 12, 13, 61 and 146. Further, more advanced
KRAS testing on a large number of patients of various ethnicities,
particularly beyond the most common hotspot alleles in exons 2
and 3 is needed to assess the prevalence and explore the exact
prognostic and predictive significance of the discovered novel
mutations as well as their possible role in colorectal carcinogenesis.
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